April 14, 2021
Business News

Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results and Provides Pipeline Review


WOODCLIFF LAKE, N.J.–()–Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and twelve months ended December 31, 2020, and reviewed key pipeline programs.

Business and Recent Highlights:

  • Posted strong year-over-year adjusted non-GAAP earnings growth of 36%;
  • Received a complete response letter (“CRL”) from U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for vasopressin. Eagle had a post-CRL meeting with FDA late last week and believes it has clear agreement on how to proceed. As previously disclosed, FDA restated that it has prioritized Eagle’s ANDA, and it is also flagged as a…



Click here to view the original article.

Related Posts

You might also like ...

MACKINAC INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mackinac Financial Corporation – MFNC
AON Splash Image
G42 Announces Investment by Silver Lake
The Equilar Diversity Network Welcomes New Partner Third Arrow Strategies Japan Board Diversity Network with a Focus on Increasing Board Gender Diversity in Japan